{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prophylaxis+B&page=2",
    "query": {
      "intervention": "Prophylaxis B",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prophylaxis+B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T16:10:43.944Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02720094",
      "title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "TDF/FTC tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for TDF/FTC tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for cabotegravir oral tablet",
          "type": "DRUG"
        },
        {
          "name": "CAB LA",
          "type": "DRUG"
        },
        {
          "name": "Placebo for CAB LA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4570,
      "start_date": "2016-12-19",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02720094"
    },
    {
      "nct_id": "NCT05693675",
      "title": "Postoperative Oral Methadone After Major Spine Surgery; Safety, Feasibility and Efficacy in Prevention of Progression to Chronic Opioid Usage at 3 Months",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Spine Surgery"
      ],
      "interventions": [
        {
          "name": "Postoperative methadone",
          "type": "DRUG"
        },
        {
          "name": "Postoperative placebo",
          "type": "DRUG"
        },
        {
          "name": "Rescue Analgesia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-10-01",
      "completion_date": "2024-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05693675"
    },
    {
      "nct_id": "NCT03741881",
      "title": "A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Haemophilia A",
        "Haemophilia A With Inhibitors",
        "Haemophilia B",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "No treatment given",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 231,
      "start_date": "2018-12-18",
      "completion_date": "2021-10-25",
      "has_results": false,
      "last_update_posted_date": "2021-11-23",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 24 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03741881"
    },
    {
      "nct_id": "NCT00601237",
      "title": "Effectiveness of a Cell Phone-Based Program for Abstinence and HIV Risk Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-related text messaging",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Nutrition-related text messaging",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "20 Years",
        "sex": "MALE",
        "summary": "16 Years to 20 Years · Male only"
      },
      "enrollment_count": 103,
      "start_date": "2008-10",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2015-04-03",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00601237"
    },
    {
      "nct_id": "NCT00364182",
      "title": "Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Recombinant Coagulation Factor IX (BeneFIX)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "6 Years to 65 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2007-05",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2011-10-04",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Chicago, Illinois • New Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00364182"
    },
    {
      "nct_id": "NCT00685425",
      "title": "Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma",
        "Bronchoconstriction"
      ],
      "interventions": [
        {
          "name": "Levalbuterol HFA MDI",
          "type": "DRUG"
        },
        {
          "name": "Racemic Albuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2002-10",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Signal Hill",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Burke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685425"
    },
    {
      "nct_id": "NCT02220985",
      "title": "Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Acute Biphenotypic Leukemia",
        "Acute Leukemia of Ambiguous Lineage",
        "Acute Undifferentiated Leukemia",
        "Allogeneic Hematopoietic Stem Cell Transplant Recipient",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Donor",
        "Lymphoblastic Lymphoma",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Myelodysplastic Syndrome With Excess Blasts-1",
        "Myelodysplastic Syndrome With Excess Blasts-2",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia in Remission"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 84,
      "start_date": "2015-03-23",
      "completion_date": "2025-05-01",
      "has_results": true,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02220985"
    },
    {
      "nct_id": "NCT01007435",
      "title": "A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo to methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1162,
      "start_date": "2009-10-31",
      "completion_date": "2014-01-28",
      "has_results": true,
      "last_update_posted_date": "2017-07-26",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 61,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01007435"
    },
    {
      "nct_id": "NCT04065399",
      "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Mixed Lineage Acute Leukemia",
        "Mixed Phenotype Acute Leukemia",
        "Acute Leukemia of Ambiguous Lineage"
      ],
      "interventions": [
        {
          "name": "revumenib",
          "type": "DRUG"
        },
        {
          "name": "cobicistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Days and older"
      },
      "enrollment_count": 447,
      "start_date": "2019-11-05",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 22,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 17 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04065399"
    },
    {
      "nct_id": "NCT06807294",
      "title": "Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chemotherapy Induced Peripheral Neuropathy (CIPN)",
        "Peripheral Neuropathy Due to Chemotherapy",
        "Peripheral Neuropathies",
        "Neuropathy"
      ],
      "interventions": [
        {
          "name": "Tai Chi Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2026-01-16",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-09-12T16:10:43.944Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06807294"
    }
  ]
}